News
Company News: A strong partnership for the management of implant-associated infections in orthopaedics and trauma surgery
— Heraeus Medical offers quick and easy access to PRO-IMPLANT Foundation’s consultation services
— Better availability of expert advice on the treatment of complex septic complications
— Interdisciplinary recommendations on treatment concept within 24 hours
Heraeus Medical and the PRO-IMPLANT Foundation combine their expertise for optimal treatment concepts of implant-associated infections in orthopaedics and trauma surgery. In the treatment of periprosthetic joint infections (PJI), the choice of an interdisciplinary, well coordinated treatment algorithm is an essential success factor.
Company News: Omnix Medical Wins €10.8M in EIC Accelerator Funding
— Novel class of anti-infectives fighting hospital-associated infections and multi-drug resistant bacteria
— Lead program OMN6 to be advanced to proof-of-concept in humans
— Antonius Schuh appointed as Chairman of the Board of Directors
Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has been awarded €10.8 million in EU funding under the EIC Accelerator Programme. The award will speed up Omnix Medical’s groundbreaking work in the fight against antimicrobial resistance based on peptides used by insects to fight bacteria.
Company News: T-knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer
T-knife GmbH, a next-generation adoptive T-cell therapy company leveraging its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, today announced the appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer. Elisa Kieback, T-knife’s co-founder and founding CEO, has assumed the role of Chief Technical Officer.
Allero Therapeutics Expands Management Team with Two Key Hires
Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, today announced the appointment of two key members to its management team.
As of December 1, 2020, Steven Glazer has joined the Company as Chief Medical Officer and Christophe Saillez as Vice President Regulatory Affairs.